Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/28/2025

Management of Rib Pain in Breast Cancer Survivors

Prevalence and Characteristics of Pain

  • Up to 50% of postmenopausal women on aromatase inhibitors report arthralgias and myalgias, with severity sufficient to cause treatment discontinuation in 20% of cases, according to the American Cancer Society 1, 2
  • The overall prevalence of musculoskeletal pain in breast cancer survivors ranges from 12% to 51% depending on the study population, as reported by the American Cancer Society 1, 2
  • These symptoms are often not responsive to NSAIDs or acetaminophen, as noted by the American Cancer Society and the Journal of Clinical Oncology 1, 2, 3
  • 25% to 60% of breast cancer survivors experience chronic pain as a result of their treatment, including surgery and radiation, according to the National Comprehensive Cancer Network 1
  • Post-radiation pain can manifest as chest wall pain, rib pain, or myofascial pain and may persist years after treatment completion, as reported by the National Comprehensive Cancer Network 4, 5
  • The incidence of chronic pain after breast surgery is as high as 60% in patients treated with breast-conserving surgery, according to the National Comprehensive Cancer Network 4, 5

Clinical Assessment and Management

  • Physical activity and exercise should be the cornerstone of management, as this is one of only two interventions with demonstrated efficacy for AI-associated pain, as recommended by the American Cancer Society and the Journal of Clinical Oncology 1, 2
  • Intensive exercise regimens reduce AI-associated pain by 20% in prospective studies, according to the American Cancer Society and the Journal of Clinical Oncology 1, 2
  • Acupuncture is the only other intervention with statistically significant improvement in AI-associated symptoms and should be offered, as recommended by the American Cancer Society, the Journal of Clinical Oncology, and Praxis Medical Insights 1, 2, 6, 3
  • Acetaminophen and NSAIDs may be offered but have limited effectiveness for AI-associated symptoms, as noted by the American Cancer Society, the Journal of Clinical Oncology, and Praxis Medical Insights 1, 2, 6, 3
  • For neuropathic pain components, duloxetine, gabapentin, or pregabalin may be considered, as recommended by the American Cancer Society and the National Comprehensive Cancer Network 1, 5
  • Switching to a different AI formulation may help, as approximately 40% of patients who discontinue one AI can tolerate another, according to the American Cancer Society and the Journal of Clinical Oncology 1, 2
  • If symptoms remain intolerable, switching from AI to tamoxifen is an option, though this changes the efficacy profile, as noted by the American Cancer Society and the Journal of Clinical Oncology 1, 2

Referral and Follow-up

  • Physical therapy or rehabilitation referral for structured exercise programs and manual therapy, as recommended by the American Cancer Society and the Journal of Clinical Oncology 1, 2
  • Pain specialist if standard interventions fail or if pain is severe, as recommended by the American Cancer Society and the National Comprehensive Cancer Network 1, 4
  • Lymphedema specialist if chest wall tightness or swelling is present, as recommended by the American Cancer Society and the Journal of Clinical Oncology 1, 2
  • Rule out recurrence or metastatic disease with appropriate imaging if pain is new, progressive, or associated with red flags, as recommended by the National Comprehensive Cancer Network 4, 5
  • Poor AI compliance increases breast cancer recurrence risk, so aggressive symptom management is essential to maintain adherence, as noted by the American Cancer Society and the Journal of Clinical Oncology 1, 2
  • AIs accelerate bone loss, approximately 2% annually in the first 5 years post-menopause, as reported by Praxis Medical Insights 6
  • Ensure adequate calcium and vitamin D3 supplementation, and consider bone density screening and bisphosphonates or denosumab if indicated, as recommended by Praxis Medical Insights and the Journal of Clinical Oncology 6, 2

REFERENCES

3

Management of Muscle Cramps in Postmenopausal Women [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

survivorship: pain version 1.2014. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2014

5

survivorship: pain version 1.2014. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2014

6

Perimenopause and Back Pain Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025